Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 364,148
  • Shares Outstanding, K 12,106
  • Annual Sales, $ 206,550 K
  • Annual Income, $ 6,090 K
  • 60-Month Beta 1.45
  • Price/Sales 1.77
  • Price/Cash Flow 3.74
  • Price/Book 1.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.86
  • Number of Estimates 1
  • High Estimate 0.86
  • Low Estimate 0.86
  • Prior Year 1.28
  • Growth Rate Est. (year over year) -32.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.36 +3.24%
on 05/14/20
40.78 -25.67%
on 05/05/20
-8.66 (-22.22%)
since 05/04/20
3-Month
28.28 +7.18%
on 03/16/20
52.22 -41.95%
on 04/14/20
-16.42 (-35.14%)
since 03/04/20
52-Week
28.28 +7.18%
on 03/16/20
86.96 -65.14%
on 07/31/19
-41.24 (-57.64%)
since 06/04/19

Most Recent Stories

More News
ANI Pharmaceuticals Provides Update on Recent Regulatory Filing

, /PRNewswire/ -- (NASDAQ: ANIP) announced today that it continues to make progress toward addressing items identified in the Refusal to File letter received from the FDA relating to its Cortrophin®...

ANIP : 30.20 (+0.40%)
ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of 16.85% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ANIP : 30.20 (+0.40%)
ANI: 1Q Earnings Snapshot

BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Thursday reported a first-quarter loss of $7 million, after reporting a profit in the same period a year earlier.

ANIP : 30.20 (+0.40%)
ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO

, /PRNewswire/ --

ANIP : 30.20 (+0.40%)
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results

, /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2020 financial results on , before the opening of the U.S. financial markets....

ANIP : 30.20 (+0.40%)
ANI Receives Refusal to File Letter from FDA for Cortrophin® Gel

ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application...

ANIP : 30.20 (+0.40%)
9.4% Return Seen to Date on SmarTrend Ani Pharmaceutic Call (ANIP)

SmarTrend identified an Uptrend for Ani Pharmaceutic (NASDAQ:ANIP) on March 18th, 2020 at $38.24. In approximately 1 month, Ani Pharmaceutic has returned 9.39% as of today's recent price of $41.83.

ANIP : 30.20 (+0.40%)
ANI Announces Upcoming Departure of CEO

ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that Arthur S. Przybyl will depart as President and Chief Executive Officer on May 10, 2020. The Board of Directors has retained a nationally...

ANIP : 30.20 (+0.40%)
ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL

ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that the U.S. Food & Drug Administration ("FDA") has accepted its supplemental new drug application ("sNDA") for Purified Cortrophin® Gel...

ANIP : 30.20 (+0.40%)
ANI Pharmaceuticals Announces Launch of Omega-3-Acid Ethyl Esters Capsules USP

ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Omega-3-Acid Ethyl Esters Capsules USP, 1 gram. The current annual U.S. market for this product is approximately $110 million,...

ANIP : 30.20 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ANIP with:

Business Summary

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone...

See More

Key Turning Points

2nd Resistance Point 32.42
1st Resistance Point 31.25
Last Price 30.20
1st Support Level 29.42
2nd Support Level 28.76

See More

52-Week High 86.96
Fibonacci 61.8% 64.54
Fibonacci 50% 57.62
Fibonacci 38.2% 50.70
Last Price 30.20
52-Week Low 28.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar